Introduction
In patients with autoimmune blood disorders, such as immune thrombocytopenia (ITP)' and neonatal granulocytopenia, IgG
Fc receptor-bearing leukocytes within the mononuclear phagocyte system (MPS) sequester and destroy blood cells coated with IgG autoantibodies. Normal monomeric human IgG (IGIV) prepared for intravenous infusion can suppress thrombocytopenia and granulocytopenia in these disorders (1) (2) (3) (4) (5) . Though IGIV also may interact with platelets directly (6) , it is well doc- umented that this agent can competitively inhibit Fc receptormediated clearance in vivo in man. Presumably the latter is a major mechanism by which IGIV reverses thrombocytopenia in adults with ITP. Unfortunately, large amounts of IGIV (2 g/kg) are required to therapeutically block immune destruction. Therefore, more efficient inhibitors of Fc receptor function might be clinically useful. Monoclonal antibodies specific for the binding site of IgG Fc receptors on macrophages (7, 8) , neutrophils (8, 9) , and natural killer cells (9) have been identified based on their capacity to potently block the interaction of IgG-coated red cells with leukocytes in vitro. Since these can bind to Fc receptors with high avidity, they also might be potent inhibitors ofthe immune clearance of IgG-coated target cells in vivo. In fact, recent studies using a monoclonal anti-human Fc receptor antibody have demonstrated the capacity of a monoclonal antibody directed against a subpopulation of Fc receptors on human macrophages to reverse thrombocytopenia in patients with ITP (10) .
In view ofthe potential clinical applications for these agents, the methodical assessment of their potency and specificity in an in vivo animal model for immune clearance seems warranted. To this end, we have studied the effects of IGIV and monoclonal anti-Fc receptor antibodies on MPS function in mice. A mouse model was chosen because prior studies have established that human, rabbit, and mouse IgG bind to Fc receptors on murine macrophages with similar avidity and specificity in vitro (1 1). Therefore, human IGIV also should block Fc receptor-mediated clearance of complexes containing rabbit or mouse IgG in vivo. In addition, the mouse is the only animal (other than man) for which well-defined monoclonal antibodies against macrophage Fc receptors (2.4G2) and complement component C3bi receptors (Mac-1) are both available (7, 12, 13 The rat-mouse hybrid cell line producing 2.4G2 (7), a monoclonal antibody which binds specifically to the IgGI/IgG2b Fc receptor on mu-50% saturated ammonium sulfate) followed by ion-exchange chromatography using DEAE-affigel blue (Bio-Rad Laboratories, Richmond, CA).
The rat-mouse hybrid cell line producing Mac-l (12, 13), a monoclonal antibody which binds specifically to the CR3 (C3bi) receptor present on murine macrophages and neutrophils, was obtained from the American Type Culture Collection (Rockville, MD). Cells were grown in culture, and antibody was purified from the resultant tissue culture medium by ammonium sulfate precipitation and ion-exchange chromatography using DEAE-cellulose (12) .
The murine hybrid cell line producing DHK, an IgG2b antibody which binds to dinitrophenyl and trinitrophenyl (TNP) groups was provided by Norman Klinman (Scripps Medical Institute, La Jolla, CA). Cells were injected intraperitoneally into pristane-primed CAFI mice and murine IgG2b monoclonal-anti-DNP/TNP antibody (DHK) was purified from the resultant ascites by affinity purification (15) Purified IgG anti-human serum albumin (anti-HSA) was prepared from rabbit anti-HSA antiserum (Cooper Biomedical Inc., Malvern, PA) by affinity purification using columns containing HSA covalently bound to Sepharose 4B and SPA-Sepharose as described previously (14) .
After purification, antibody preparations contained greater than 90% IgG as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using reduced 12% or unreduced 5% polyacrylamide gels. Protein concentrations were determined using standard methods (16) . The extent of aggregation of IgG preparations was assessed by gel filtration chromatography using Sepharose 4B (Pharmacia Fine Chemicals).
IGIV (Gamimune IV) was provided by Cutter Laboratories (Berkeley, CA) at a concentration of 50 mg/ml. This preparation was prepared by ethanol precipitation of pooled human plasma from normal volunteers. Based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, greater than 95% of the protein in this preparation is human IgG. To eliminate spontaneous aggregation, the product was equilibrated by the manufacturer in alow pH buffer (pH 4.25) containing 10% maltose, but the IgG in this preparation was not chemically modified in any other manner. The manufacturer has established that IGIV, in the doses used in these studies, does not significantly alter intravascular pH in animals.
Human IgG aggregates were prepared by heating IGIV, which had previously been dialyzed in PBS (pH 7.2) to remove maltose, at 63°C for 30 min (17) . After heating, the preparation was turbescent, indicating the formation of colloidal aggregates of IgG. Aggated IgG preparations routinely were stored at 4°C and used within 24 h after heat treatment.
Fc receptor-mediated clearance ofantibodycoated red cells. To study the clearance of red cells coated with murine IgG, we assessed the rate of disappearance of autologous TNP-red cells (TNP-Es) coated with IgG2b DHK antibody (TNP-EAs). TNP-Es were prepared (18) from 40 Ml of blood removed from the retroorbital complex of mice using a calibrated microcapillary tube (Accuppette Pipets, Dade Diagnostics, Aquada, Puerto Rico). After three washes with PBS, red cells were incubated with a 0.25-0.33 mg/ml solution of trinitrobenzene sulfonic acid (TNBS) dissolved in PBS (pH 7.0) for 30 min at room temperature. After excess TNBS was washed away, cells were washed once with 5 mM glycylglycine and then three additional times with PBS. To radiolabel cells, TNP-Es were incubated with 10 MCi of sodium chromate containing 5tCr (Amersham Corp., Arlington Heights, IL) for 30 min at 37°C and then washed three additional times. TNP-EAs were prepared by incubating these labeled cells for 30 min at room temperature with varying amounts of DHK (anti-TNP) just before infusion intravenously.
To study the clearance of EAs not bearing TNP groups on their surface, autologous Es were coated with rabbit anti-mouse red cell antibody. To this end, the packed red cells from 40 A of blood were51C- In our experience, the rate of disappearance of Es was quite reproducible over time; however, the rate ofdisappearance of TNP-Es, TNPEAs, and EAs varied slightly with changes in the batch of TNBS or of antibody. Therefore, studies ofthe clearance of TNP-Es, TNP-EAs, and EAs in PBS-treated control animals (performed using the identical reagents during the same 1-2 wk period) always were performed in parallel with clearance studies in animals treated with putative MPS inhibitors.
To assess the sites ofsequestration ofEs and EAs, animals were killed 3 h after red cell infusion, and the amount of radioactivity within the blood, liver, spleen, lungs, heart, stomach, intestines, and kidneys measured directly using a gamma emission spectrometer. The total amount of radioactivity in the vasculat space was calculated assuming the total blood pool equals 7% of body weight. The amount of radioactivity in each organ then was expressed as a percent of total counts recovered at the time ofkilling. Since only small amounts ofradioactivity were present in non-MPS sites, for simplicity, only sequestration within the liver, spleen, lungs, and blood has been presented. Fc receptor-mediated hepatic sequestration ofHSA-anti-HSA immune complexes. This was quantitated using previously described methods (14, 19) . In brief, purified IgG anti-albumin was radiolabeled with 123I (19), using lodogen (1 ug and 50 ,uCi of radioactive iodine per 10 ,ug of protein). Radiolabeled HSA-anti-HSA complexes were prepared by mixing anti-HSA antiserum, trace-labeled with 1251 labeled purified anti-HSA (1 Mg of labeled antibody per 50 gl of antiserum) with fivefold excess of HSA. Using gel filtration chromatography, we have previously shown that labeled anti-albumin in the absence ofantigen migrates with the molecular weight of monomeric IgG, but after incubation with albumin, substantial amounts of immune complexes are formed (14) . To measure clearance, radiolabeled HSA-anti-HSA complexes containing 2 Al of anti-serum per gram body weight were infused intravenously. 90 min later, 10 Ml of packed autologous red cells (labeled with 200,000-400,000 cpm of 5"Cr) were infused and 10 min later (after equilibration of the red cells within the vascular space) duplicate IO-MI samples of blood were obtained and animals were killed by cervical dislocation.
Radioactivity due to 5"Cr and 125I within the visceral organs (as noted above) was measured using a two-channel gamma emission spectrometer. After radioactivity due to blood trapping was deducted from total radioactivity, the percent of total recoverable '25I-labeled complexes sequestered extravascularly in each organ at the time of killing was calculated (14) . To assess the effects of inhibitors on Fc receptor-mediated hepatic sequestration ofimmune complexes, HSA-anti-HSA sequestration was assessed 90 min after the intraperitoneal infusion of each inhibitor or after the infusion of a comparable volume of PBS.
The percent inhibition of Fc receptor-mediated hepatic sequestration was calculated using the formula:
where HSA-anti-HSA'Pli" is the percent hepatic sequestration in animals receiving a putative MPS inhibitor prior to immune complexes;
HSA-anti-HSAct3"l is the percent sequestration in animals pretreated only with PBS; and (anti-HSA) is the percent hepatic sequestration of labeled anti-HSA administered in the absence ofantigen in animals pretreated with PBS. Prior studies have established that 2.4G2, a known inhibitor of immune complex clearance (14) , even at high doses does not alter (anti-HSA) sequestration in the absence of antigen. Heat-damaged red cells. Heat-damaged red cells were prepared (21) from thrice washed Es obtained from 40 Ml ofheparinized blood obtained from the retroorbital space using calibrated pipets as described above.
The cells, suspended in I ml of PBS in a 12 X 75 mm glass tube, were heated at 49.5°C for 10 min within a Lauda K-2 thermostat adjusted to 49.50C, washed, and then labeled with 5'Cr. The rate of disappearance ofheated red cells from the circulation was monitored as described above.
Serum hemolytic complement. Serum hemolytic complement was measured by incubating twofold dilutions of serum (50 ,ul) from treated or control animals with 30 Ml of a 1:5 dilution of a heat-treated (560C for 10 min) rabbit anti-sheep red cell hemolysin antiserum and 10 ;l of a 0.4% solution ofthrice-washed sheep red cells. All reagents were diluted in a veronal-buffered saline containing 0.5 mM calcium chloride and 1 mM magnesium chloride (22) . The mixture was incubated at 370C for 1 h, at which time unlysed red cells were pelleted by centrifugation at 1,000 g for 10 min, and the absorbance produced by released hemoglobin was quantitated spectrophometrically at 412 nM. Because of the lability of mouse complement, assays always were performed using freshly obtained serum. The CH50 titer was estimated from plots of log (serum concentration) versus log (fraction of red cells lysed)/( I -fraction of red cells lysed) (22) .
Complement depleted mice. Complement-depleted mice were prepared by injecting 2.5 U of CVF in 0.5 ml of PBS intraperitoneally at 12-h intervals for a total of four doses (23) . Hemolytic complement assays and clearance studies were performed 18 h after the last dose of CVF. Hemolytic complement in animals treated in this manner was undetectable in our assay, representing at a minimum a 32-fold reduction in hemolytic complement levels compared to control mice. Blood leukocyte concentrations. Blood leukocyte concentrations in treated animals were assessed serially after treatment with IGIV or monoclonal antibodies, using a hemocytometer. Microhediatocrits were determined using microcapillary tubes by standard clinical techniques.
Statistics. Confidence limits in all instances represent the standard deviation of the mean. The significance ofdifferences between results in varying groups were assessed using the standard two-tailed t test for unpaired samples.
Results
The extent of aggregation in the IgG preparations used to treat animals in these studies was assessed by gel filtration chromatography using Sepharose 4B (Fig. 1) . IGIV and Mac-I migrated as a single peak of monomeric IgG. The monoclonal anti-Fc receptor antibody 2.4G2 also was predominantly monomeric (97%), although small amounts of aggregates could be detected.
As expected, heat-treated IgG contained a heterogeneous mixture of aggregates and residual monomers.
Consistent with the reported tendency ofheavily TNP-coated red cells to be ingested by macrophages (24), radiolabeled TNPEs infused into mice in the absence of antibody were cleared more rapidly than unmodified Es. However, at the level of TNP coating employed in these studies, more than half ofthe infused red cells remained in the blood for at least 4 h. When TNP-Es TUBE NUMBER Figure 1 . Comparison of the pattern of elution from Sepharose 4B of the IgG MPS blockers. 100 Ml of each preparation was passed through a I X 30-cm column of gel, and the absorbance at 280 nm was monitored in each 0.7-ml fraction.
were sensitized with increasing amounts of DHK to form TNPEAs, the rate of disappearance accelerated in a dose-dependent manner (Fig. 2) . The acceleration of clearance was antigen-dependent since even 64 ug of DHK did not alter the rate of disappearance of Es uncoated with TNP (data not shown). An antibody dose of 40 ,ug routinely was used to sensitize TNP-Es for subsequent studies.
Intraperitoneal infusions of as little as 4 Mig per gram body weight of2.4G2 almost completely inhibited antibody-dependent clearance of TNP-EAs (Fig. 3 ). At either 16 or 8 gg/g doses of 2.4G2, EA clearance differed from that in control animals with P < .001. Monomeric IGIV also profoundly blocked antibodydependent clearance, albeit at 100-1,000-fold greater concentrations than 2.4G2 (Fig. 4) . At ,gg/g body weight (data not shown).
Though this model for immune hemolysis has the advantage of utilizing a murine antibody to mediate clearance, since at high levels TNP coating can induce ingestion of red cells by MPS cells even in the absence of antibody (24), the results obtained might not accurately reflect normal red cell immune clearance. Therefore, we also have studied the clearance of EAs. EAs disappear rapidly from the blood in normal mice. Although no single agent completely inhibited Fc receptor-mediated clearance of EAs, mice pretreated with 16 gg/g of 2.4G2, or 2,000 gg/g of IGIV, cleared these cells much more slowly than control animals (P < 0.001). Animals pretreated with Mac-l cleared EAs as rapidly as controls (Fig. 6) . These results are qualitatively quite similar to those obtained using TNP-EAs.
Since TNP-coated Es may be sequestered even in the absence of antibody, the effects of MPS blockers on the pattern of red cell sequestration was studied using Es and EAs exclusively. The pattern of sequestration of EAs in blood and the MPS is illustrated in Table I . 3 h after infusion into control mice, most EAs All points represent the mean for groups of three animals, and the bars represent the standard deviations. were sequestered in the liver and (to a more variable extent) in the spleen. Pretreatment with Mac-l did not significantly alter this pattern of sequestration. Pretreatment with 2.4G2 or IGIV, however, very significantly reduced sequestration within the liver, and increased the fraction of cells remaining within blood. Splenic sequestration, on the average, also was reduced by these agents, but this difference achieved statistical significance only in IGIV-treated animals. We have demonstrated previously that 2.4G2 can block the clearance of soluble HSA-anti-HSA immune complexes (14) . IGIV and heat-aggregated IgG also inhibited the clearance from blood and sequestration in the liver ofHSA-anti-HSA complexes (Table II) . As in studies of the clearance of EAs, 2.4G2 blocked the cleira'nce of soluble HSA-anti-HSA immune complexes at much lower doses than IGIV or heat-aggregated IgG (Fig. 7) . To assess the specificity of MPS blockade, the effect of each agent on the clearance of heat-damaged Es was studied. Monomeric IGIV did not alter the rate ofclearance ofheat-damaged Es, but 2.4G2 and Mac-l very significantly slowed their disappearance from blood. Heat-aggregated IgG also significantly reduced clearance compared to control animals, but this difference was less striking (Fig. 8 and Table III) .
To assess the effects of inhibitors on complement levels in serum, blood hemolytic complement levels were compared before and 90 min after inhibitor infusions. IGIV did not reduce complement activity, but both monoclonal 2.4G2 and Mac-I reduced complement levels substantially and heat-aggregated IgG depleted serum of complement (Table IV) .
To assess the role of complement on EA clearance, the MPS function of animals depleted of complement by the infusion of CVF was assessed. CVF treatment substantially reduced the rate ofEA disappearance (Fig. 9) , confirming that complement played a significant role in clearance in this model. Mechanically, the reduced rate of red cell destruction following CVF treatment might result either from reduced fixation of the terminal complement components needed for the intravascular hemolysis of EAs, or from decrease fixation of C3b, a component capable of enhancing the immune adherence of EAs to phagocytes within the MPS (25) . When labeled Es and EAs were incubated with serum in vitro for 2 h at 37°C, in each oftwo experiments there was less than 10% 5"Cr release from Es, but 27% and 45% release from EAs. Thus, it is likely that the effect of CVF in part results from the blockade of complement-mediated intravascular hemolysis. In addition, since CVF treatment also reduced hepatic sequestration of EAs (Table V) , it is likely that the latter mechanism also was important in vivo.
Since complement components play an important role in the elimination of EAs, the partial depletion of complement components observed following the infusion of 2.4G2 may contribute to its inhibitory effect on immune clearance. However, 2.4G2 clearly had a substantial independent effect on Fc receptor function even in CVF-treated animals without measurable hemolytic complement activity. In fact, though neither 2.4G2 nor CVF alone could completely block immune clearance, treatment with both agents caused a profound inhibition in the clearance of EAs from the blood (Fig. 9 ) and in the sequestration of EAs within the liver and spleen (Table V) .
To assess whether complement depletion affected heat-damaged red cell clearance, the rates ofdisappearance were compared in control and CVF-treated animals. CVF-treated animals with <3% of normal complement levels cleared heat-damaged red cells no more slowly than control animals (data not shown). (26), IgG aggregates (27) , and anti-Fc receptor antibodies (7) (8) (9) , each can competitively inhibit antibody-dependent, leukocyte-mediated destruction of EAs in vitro. The goals of these studies were to compare the efficacy of IGIV and monoclonal anti-macrophage antibodies in blocking Fc receptor function in vivo, and to assess the effects of each agent on other aspects of MPS function. Our results indicate that anti-receptor antibodies are much more potent inhibitors of immune function in vivo than IGIV, but that this increase in potency is achieved at the expense of some loss in specificity of action.
To study the effects of IGIV and monoclonal antibodies on IgG antibody-coated target cell clearance, we measured clearance in vivo of TNP-Es coated with anti-TNP and of EAs. The antibody-dependent destruction of TNP-EAs could be almost completely inhibited using several Fc receptor blockers, suggesting that clearance was mediated predominantly by Fc receptor bearing leukocytes. Though Fc receptor blockade also inhibited EA disappearance, destruction of these cells could not be as completely inhibited using Fc receptor blockers alone. Since our EAs could fix sufficient complement to produce measurable complement-dependent lysis in vitro, and since complement depletion and Fc receptor blockade seemed to exert separate and additive inhibitory effects on EA destruction in vivo, we presume that the terminal components of complement also contributed to lysis in this model.
In prior guinea pig and human studies of Fc receptor-mediated clearance (utilizing EAs which did not fix complement extensively), cell sequestration occurred predominantly in the spleen (25, 28) . In contrast, most EAs in the current studies were trapped within the liver. Since C3b coating is known to facilitate hepatic sequestration (25, 28) , this difference in pattern ofuptake may reflect the greater levels ofcomplement components bound to our EAs compared to those used in prior studies. In addition, it is conceivable that species-related differences in MPS structure and function also may have played a role.
Complement components as well as IgG often are found on the surface of red cells from patients with immune hemolysis (28) and on platelets from patients with ITP (29). When present, such components commonly may play a significant role in facilitating MPS sequestration. Less commonly, IgG antibodies fix sufficient complement to cause clinically significant intravascular lysis (29). Obviously, the potential effectiveness of Fc receptor blockade alone as a strategy for inhibiting immune destruction diminishes as the role ofcomplement in directly lysing cells increases. However, our studies using EAs illustrate that even when significant amounts of complement are bound to target cells, Fc receptor blockade still can reduce immune destruction substantially.
IGIV was an effective inhibitor of Fc receptor-mediated clearance ofTNP-EAs, EAs, and immune complexes. Since there are significant species differences in the amino acid structure of IgG, not all species of heterologous IgG would be suitable as a blocking agent in a murine model. However, since prior studies have established that murine, rabbit, and human IgG each bind to IgG2a and IgG2b/IgGl Fc receptors on murine leukocytes with comparable avidity in vitro (1 1), we felt it reasonable to use human IgG to competitively inhibit murine Fc receptor function in vivo. In fact, the dose of IGIV required to produce high grade inhibition of murine Fc receptor function (2 mg/g body weight) was identical to that found empirically to reverse thrombocytopenia in patients with ITP (1-4), suggesting that IGIV has similar efficacy in mouse and man. Since IGIV already is in active use in blocking Fc receptor function in patients with autoimmune blood disorders, it was reassuring to observe that this agent appears to be a very selective inhibitor of MPS function. MPS clearance of heat-damaged red cells, blood leukocyte concentrations, and serum hemolytic complement activity were unaffected even by large IGIV infusions.
Human IgG aggregates block Fc receptor function in vitro more efficiently than IgG monomer, presumably as a result of the greater avidity with which multivalent complexes bind to Fc receptor-bearing cells (30, 31) and to the capacity of such complexes to downregulate Fc receptors (32) . In vivo aggregates were comparable in potency or slightly more potent than mo- We have previously demonstrated that 2.4G2 very potently inhibits MPS clearance of immune complexes (14) . Indeed, 2.4G2 also blocked EA clearance with similar potency. This antibody also partially depleted serum hemolytic complement, presumably by fixing components to the surface of antibodycoated leukocytes. In view of this, 2.4G2 conceivably might decrease EA clearance not only by blocking Fc receptors but also by decreasing the amount of C3 or other complement components fixed to red cells. Clearly, the profound effect of 2.4G2 on immune clearance is not merely a consequence of complement depletion, since 2.4G2 still dramatically reduces Fc receptor function even in animals depleted ofcomplement by prior treatment with CVF. In fact, our data ( Fig. 9) dramatically illustrate the additive effect of complement depletion and Fc receptor blockade in preventing IgG mediated immune clearance.
Prior in vivo studies have demonstrated a role for C3b and possibly for C3bi in the immune clearance of IgG-coated red cells (25) . However, Mac-l, an antibody which blocks C3bi receptor function (13) In view of this, 2.4G2 and Mac-I presumably inhibit nonspecific MPS function either by altering MPS cell function by some other as yet unknown mechanism or by significantly altering the rate of blood flow through the liver and spleen.
A similar blockade of MPS phagocytic function can be produced by the infusion of colloids in vivo. Colloids block MPS function both by interfering with the phagocytic function ofleukocytes and by depleting serum of opsonic factors, especially fibronectin (34) . Anti-macrophage antibodies could inhibit MPS function by initiating complement-mediated destruction of macrophages, but this is unlikely for two reasons: (a) mouse serum does not lyse 2.4G2-or Mac-I-coated murine cells (12) , and (b) 2.4G2 can nonspecifically inhibit MPS function even in C5 deficient animals (14) . Conceivably the noncytotoxic binding of complement components to cells, or the depletion of serum opsonic factors may account for the inhibition noted in these studies. This mechanism of suppression requires further evaluation in view of the growing interest in the use of a variety of monoclonal anti-leukocyte antibodies as therapeutic agents.
Our (37) . Clinically, IGIV often benefits patients with autoimmune blood disorders, but because of the very large quantities required it is difficult and expensive to maintain chronic suppression of immune destruction, especially in adults, using this agent. Therefore, the recent report ofClarkson et al. (10) demonstrating that a monoclonal antibody directed against the low avidity Fc receptor present on human neutrophils and macrophages can correct thrombocytopenia in patients with ITP is ofgreat interest. In view of our results, it will be of interest to see whether reductions in complement levels and/or defects in MPS function comparable to those reported in this manuscript also will be observed following infusion of anti Fc receptor antibody in a clinical setting. If so, attempts to minimize these changes may be warranted, since defects in MPS function may impair the host response to some types of stress (34) .
